Renal, Cardiovascular and Safety Outcomes of Canagliflozin in Patients with Type 2 Diabetes and Nephropathy in East and Southeast Asian Countries: Results from the CREDENCE Trial. 

Wada T, Mori-Anai K, Kawaguchi Y, Katsumata H, Tsuda H, Iida M, Arakawa K, Jardine MJ.
J Diabetes Investig. 2021 Jul 1. doi: 10.1111/jdi.13624. Online ahead of print.PMID:34212533